Celgene's (CELG -0.2%) Apremilast treatment for psoriatic arthritis was effective in a Phase III trial and had no major safety problems. The study is the first of three trials of the drug, and Celgene expects to file for FDA approval in H1 next year. (PR)
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Tue, 6:33PM)
at Investor's Business Daily (Fri, 6:51PM)
Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst Blogat Zacks.com (Feb 26, 2015)
at Nasdaq.com (Feb 24, 2015)
at Zacks.com (Feb 23, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs